Main content

    Stroke / TIA Clinical Trials

    Sutter Health participates in clinical trials related to Stroke and TIA throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: Albumin in Acute Stroke (ALIAS) Trial-Part 2: A Phase III, Randomized, Multicenter Clinical Trial of High-Dose Albumin Therapy for Neuroprotection in Acute Ischemic Stroke (National Institute of Neurological Disorders and Stroke) (NINDS, 2U01NS40406-04
    Description: The goal of the trial is to determine whether human albumin, administered within 5 hours of symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Acute ischemic stroke with NIHSS >6; able to enroll within 5 hours of stroke onset
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke (MILESTONE)
    Description: The primary objective is to determine the effect of two dose strengths of dalfampridine-ER tablets, taken twice daily for 12 weeks, on stable-walking deficites in subjects with post-ischemic stroke.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients 18 and older with stable walking deficit due to ischemic stroke that occurred six months prior or more, with BMI 18-35 kg/m2
    Status: Active and enrolling
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, RN, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: IV Thrombolysis in Anticoagulated Acute Stroke Patients
    Description: Retrospective study of outcomes and safety of patients who receive off-label IV rt-PA despite full anticoagulation
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Retrospective
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: Platelet- Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
    Description: A prospective randomized double-blind multicenter trial; the primary objective is to determine whether clopidogrel 75mg/day bu mouth after loading dose of 600mg of clopidogrel is effective in preventing major ischemic vascular events ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of TIA or minor ischemic stroke onset in patients receiving aspirin 50-325 mg/day.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: TIA or minor stroke; must be enrolled within 12 hours of symptom onset.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: Expanding the Time Window for IV Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Using Computed Tomography Perfusion Imaging: The PERFusion Use in Stroke Evaluation (PERFUSE) Study (Sutter Pacific Medical Foundation
    Description: A phase II trial, evaluating the utility of 64 slice CT perfusion (CTP) in acute ischemic stroke (AIS) patients. The main aim is to determine which aspects of CTP imaging can aid in expanding the time window for thrombolysis with IV (rt-PA) in AIS patients up to 6 hours after symptom onset.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Active ischemic stroke within 6 hours of symptom onset received IV rt-PA and have CT perfusion imaging
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Katie Ponting, 415-600-1163
    Email: PontinK@cpmri.org

    Title: Advancing Telestroke Care: A Prospective Observational Study
    Description: This study will promote the development and economic sustainability of telemedicine for acute stroke treatment.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Patients treated for acute or subactue ischemic stroke in participating hospitals.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
    Description: A multicenter, randomized, controlled clinical trial of 1400 patients. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.
    Investigator: Nobl Barazangi, MD PhD
    Eligibility: Acute ischemic stroke within 12 hours of stroke onset, with a known history of diabetes or hyperglycemia on admission.
    Status: Active and soon open CPMC to enroll
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: Neuroform Micordelivery Stent System
    Description: Placement of cerebral coils/stents after stroke
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, 510-727-8267
    Email: ndunguc@sutterhealth.org

    Title: Wingspan Stent System With Gateway PTA Balloon Catheter
    Description: Placement of cerebral coils/stents after stroke
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, 510-727-8267
    Email: ndunguc@sutterhealth.org

    Title: The S.M.A.R.T. Approach to Stroke Treatment
    Description: To evaluate, retrospectively, CPMC's Comprehensive Stroke Care Center's experience with the Simplified Management of Acute stroke using Revised Treatment criteria (SMART) approach towards treating stroke patients
    Investigator: David Tong, MD
    Eligibility: Retrospective study of all stroke patients treated at CPMC, especially those receiving acute stroke therapy
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Jessica Redford, RN 415-600-1781
    Email: RedfordJ@cpmri.org

    Title: Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients with Stable Ischemic Stroke (Protocol SB-STR01)
    Description: The primary objective of this project is to prescreen Sutter neurology patients who have been diagnosed with an ischemic stroke through chart review and visit with physican, to determine if they are eligible for the study titled: “A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients with Stable Ischemic Stroke
    Investigator: Gregory LeBleu, MD
    Eligibility: Patients 18-75 with a history of one (1) ischemic stroke, who are six (6) months to three (3) years out from Stoke and not improving in medical health.
    Status: Not currently enrolling
    Location: Sutter Rehab/SNI/SIMR
    Contact: Debbie Jacobs, RN, 916-453-5745
    Email: jacobsda@sutterhealth.org

    Title: WEAVE
    Description: WEAVE Trial: Wingspan Stent System Post Market Surveillance Study. The primary objective of this study is to evaluate the rate of stroke and death in patients treated with the Wingspan Sten Sustem, according to the indications for use, within 72 hours post procedure.
    Investigator: David Bonovich, MD
    Eligibility: All patients for whom treatment with the Wingspan Stent System is considered.
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, 510-727-8267
    Email: ndunguc@sutterhealth.org

    Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
    Description: The Primary Specific Aim of this randomized, double-blind, multicenter clinical trial is to determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg is effective in improving survival free from ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of onset of TIA or minor ischemic stroke in patients receiving aspirin 50-325 mg/day.
    Investigator: Wendy Brown, MD
    Status: Enrolling, but on hold
    Location: Sutter Roseville Medical Center
    Contact: Michele Guillen, CCRC, 916-781-1613
    Email: Guillem1@sutterhealth.org

    Title: PROSPER - Patient-centered Research into Outcomes Stroke patients Prefer and Effectiveness Research
    Description: PROPER is a three year research project to create a national, sustainable model to improve decision-making and patient-centered stroke outcomes through comparative effectiveness research.
    Investigator: David Bonovich, MD
    Eligibility: Patients ≥18 and with a primary diagnosis of acute ischemic stroke.
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, (510) 727-8267
    Email: ndunguc@sutterhealth.org

    Title: Wingspan Stent System With Gateway PTA Balloon Catheter
    Description: Placement of cerebral coils/stents after stroke.
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only.
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, (510) 727-8267
    Email: ndunguc@sutterhealth.org

    Title: Neuroform Micordelivery Stent System
    Description: Placement of cerebral coils/stents after stroke.
    Investigator: David Bonovich, MD
    Eligibility: Subjects undergoing brain coil/stent placement - Humanitarian use device only.
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, (510) 727-8267
    Email: ndunguc@sutterhealth.org

    Title: Trevo® Retriever Registry Post Market Surveillance
    Description: The purpose of the Trevo® Retriever Registry is to collect real world performance data of the Trevo Retriever which is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
    Investigator: David Bonovich, MD
    Eligibility: Subjects experiencing acute ischemic stroke who are eligible for restoration of blood flow using any approved Trevo Retriever in the neurovasculature to remove thrombus and the Trevo Retriever is the initial mechanical neuro-thrombectomy device used to remove the thrombus.
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, (510) 727-8267
    Email: ndunguc@sutterhealth.org

    Title: ARAMIS – Addressing Real-world Anticoagulant Management Issues in Stroke
    Description: The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice.
    Investigator: David Bonovich, MD
    Eligibility: Patients who have had an acute ischemic stroke that has taken either dabigatran, rivaroxaban, apixaban, or edoxaban at least 7 days prior to admission OR patients who have had an intracerebral hemorrhage that has taken warfarin or one of the novel oral anticoagulants at least 7 days prior to admission.
    Status: Active and open to enrollment
    Location: Eden Medical Center
    Contact: Catherine Ndungu-Case, (510) 727-8267
    Email: ndunguc@sutterhealth.org

    > See All Neurology Clinical Trials by Condition